Here are five things you need to know this morning:, showing higher than expected profit and boosted guidance for the rest of the year. Adjusted earnings for the year will come in between US$2.75 and $2.95 a share for the year, the pharma giant says. That’s up 30 cents from the previous forecast. A big reason for the improved showing is resurgent sales of anti-viral drug Paxlovid, which soared to $2.7 billion.
like Europe, China and the Middle East, even as its home market of the U.S. eked-out growth. Sales at restaurants open for at least 13 months fell by 1.5 per cent during the quarter. That’s more than twice as bad as the 0.6 per cent drop that analysts were forecasting. In the U.S. they inched up 0.3 per cent. Despite the sales slowdown, the company posted adjusted earnings of US$3.23 a share. That’s better than the $3.19 last year and better than what analysts were expecting.
. The technology giant is expected to post adjusted earnings of US$1.84 a share, on revenue of $86.37 billion. That’s up from $1.55 and $76.7 billion last year. Alphabet shares have gained 19 per cent this year, underperforming the broader S&P 500 index.